Christensen B, et al. - Researchers assessed the safety and efficacy of induction therapy with calcineurin inhibitors in combination with vedolizumab for patients with Crohn's disease (CD) or ulcerative colitis (UC). Data on patients with CD or UC who started treatment with vedolizumab from May 20, 2014, through March 30, 2015, and received calcineurin inhibitors (tacrolimus or cyclosporin) during the first 12 months of vedolizumab therapy was collected. In patients with CD and UC with up to 52 weeks of follow-up, combination therapy of vedolizumab with either cyclosporin or tacrolimus was effective and safe at inducing and maintaining clinical remission.